INNOVATION FOR LIFE

— Welcome to DIAGENICS

Product Lines

Get a first impression of our products and learn more about our product lines.

Note

Rapid Antigen Tests*

Our rapid antigen tests are already registered on the BfArM list according to the Paul Ehrlich Institute / Robert Koch Institute and WHO criteria for Covid-19 antigen tests.

The diagnostic antigen rapid test is for the direct detection of the antigens of Covid-19. The sample is obtained through a simple nasal swab. The virus is detected within 10-15 minutes based on the lateral flow principle.
*Rapid antigen tests are only supplied to doctors and medical specialists, authorities, teachers and educators.
DIAGENICS Group SE

Professional Diagnostics

Diagenics Group SE is a biopharmaceutical enterprise with branch offices and partners in Europe and the USA. We are developers and producers of a new line of diagnostic products based on a new and innovative bio-marker. The potential of our products will change and improve the medical diagnosis.

Recommended by

The early detection of emergencies such as heart attack and stroke is one of the key factors and it has a decisive influence on the life-or-death of the affected people. With the development of our innovative diagnostic products, it is our goal to find better and more effective solutions for the early identification of such essential health disorders.

Virology

177.000.000+
COVID-19 Fälle

Gynecology

10.000.000
Präeklampsiepatienten

Cardiology

77.000.000
Herzinfarktpatienten

Neurology

15.000.000
Schlaganfallpatienten

Diagenics Group SE is a biopharmaceutical company and is a pioneer in innovative diagnostics for the early detection of important diseases such as heart attack (ACS), stroke and preeclampsia. This early detection is based on a new and innovative biomarker that was developed by Diagenics Group SE. Diagnostic results are faster and more accurate, which in turn is inexpensive and reduces the frequency of misdiagnosis.

DIAGENICS Group SE

Clinical Partners